Acts and Regulations

2008-54 - Designated Materials

Full text
Contents of pharmaceutical products and medical sharps stewardship plan
2022-73
50.76A pharmaceutical products and medical sharps stewardship plan shall contain the following:
(a) the plan for the collection, transportation, storage and processing of pharmaceutical product and medical sharp waste within the Province, including the pharmaceutical product and medical sharp waste of other brand owners;
(b) information on the expected quantity or weight of pharmaceutical products and medical sharps, by material type, to be distributed within the Province and the expected quantity or weight of pharmaceutical product and medical sharp waste, by material type, to be collected or processed;
(c) information on the province-wide collection system, including information with respect to return facilities, by material type, to be used by the consumer;
(d) a description of how existing collection and processing systems were considered to maximize waste diversion in the Province;
(e) the geographical areas that will be used for annual reporting purposes;
(f) the plan for the provision of services to remote or rural areas;
(g) the plan for the management of pharmaceutical product and medical sharp waste, by material type, in adherence to the following order of preference:
(i) recycling;
(ii) recovery of energy; and
(iii) disposal in compliance with the Act;
(h) information on current and future research and development activities in the Province related to the management of pharmaceutical products and medical sharps;
(i) the communications plan to inform consumers of the stewardship plan, including the consumer’s reasonable and free access to collection methods;
(j) the location of any long-term storage, containment or final treatment and processing facilities for pharmaceutical products and medical sharps;
(k) a description of how pharmaceutical product and medical sharp waste will be managed, by material type, in a manner that employs environmental, human health and safety standards that meet or are more strict than applicable laws;
(l) the plan for the elimination or reduction of the environmental impacts of pharmaceutical product and medical sharp waste, by material type;
(m) a description of greenhouse gas emission impacts that will result from the implementation of the stewardship plan and opportunities for reducing those impacts;
(n) a description of the material types that will be used for performance measures and targets and annual reporting purposes; and
(o) a dispute resolution procedure to deal with disputes arising between the brand owner and a service provider.
2022-73